Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. - Kumar S; Jagannath S; Weisel KC; Rosiñol L; Leleu X; Dimopoulos MA; Kastritis E; Siegel DS; Monge J; Du J; de la Rubia J; Asensi Cantó P; et al. (Blood cancer journal, 2026)